PL2323623T3 - Kompozycje farmaceutyczne - Google Patents
Kompozycje farmaceutyczneInfo
- Publication number
- PL2323623T3 PL2323623T3 PL09806425T PL09806425T PL2323623T3 PL 2323623 T3 PL2323623 T3 PL 2323623T3 PL 09806425 T PL09806425 T PL 09806425T PL 09806425 T PL09806425 T PL 09806425T PL 2323623 T3 PL2323623 T3 PL 2323623T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08162213 | 2008-08-12 | ||
| EP08165662A EP2172189A1 (en) | 2008-10-01 | 2008-10-01 | Pharmaceutical Compositions |
| EP09151917A EP2213307A1 (en) | 2009-02-03 | 2009-02-03 | Injectable depot formulations |
| EP09806425.6A EP2323623B1 (en) | 2008-08-12 | 2009-08-11 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2323623T3 true PL2323623T3 (pl) | 2017-04-28 |
Family
ID=41020843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09806425T PL2323623T3 (pl) | 2008-08-12 | 2009-08-11 | Kompozycje farmaceutyczne |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9155696B2 (pl) |
| EP (1) | EP2323623B1 (pl) |
| JP (2) | JP5951991B2 (pl) |
| KR (1) | KR101626632B1 (pl) |
| CN (1) | CN102119022B (pl) |
| AU (1) | AU2009281223B2 (pl) |
| BR (1) | BRPI0917975A2 (pl) |
| CA (1) | CA2731316C (pl) |
| ES (1) | ES2600797T3 (pl) |
| MX (1) | MX347056B (pl) |
| PL (1) | PL2323623T3 (pl) |
| PT (1) | PT2323623T (pl) |
| RU (1) | RU2504360C2 (pl) |
| WO (1) | WO2010018159A1 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9314509B2 (en) | 2009-11-16 | 2016-04-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
| EP3378468A1 (en) | 2010-01-13 | 2018-09-26 | Ipsen Pharma S.A.S. | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
| WO2011115871A1 (en) * | 2010-03-15 | 2011-09-22 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of growth hormone secretagogue receptor ligands |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| LT2394664T (lt) * | 2010-05-31 | 2016-09-26 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsichozinė injekcinė depozitinė kompozicija |
| RU2015115649A (ru) * | 2012-09-27 | 2016-11-20 | Октафарма Аг | Тест на гемолитический потенциал фармацевтических продуктов и составов для минимизации риска |
| KR20150129717A (ko) * | 2013-03-14 | 2015-11-20 | 젠자임 코포레이션 | 열-감수성 골 성장 조성물 |
| EP2823808A1 (en) | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| WO2015133580A1 (ja) * | 2014-03-05 | 2015-09-11 | わかもと製薬株式会社 | 注入可能なポリ乳酸類含有組成物 |
| JO3394B1 (ar) | 2014-07-04 | 2019-10-20 | Osteo Pharma B V | تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام |
| EP3331495B1 (en) | 2015-08-03 | 2020-11-04 | Tolmar International Limited | Liquid polymer delivery system for extended administration of drugs |
| EP3352735B1 (en) | 2015-09-21 | 2023-08-30 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulations |
| GB201519811D0 (en) * | 2015-11-10 | 2015-12-23 | Univ Belfast | Ocular compositions |
| CN106822043A (zh) * | 2017-01-24 | 2017-06-13 | 广州帝奇医药技术有限公司 | 利培酮缓释组合物及其制备方法 |
| AU2018238136A1 (en) | 2017-03-20 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| WO2018227293A1 (en) * | 2017-06-13 | 2018-12-20 | The University Of British Columbia | Polymeric paste compositions for drug delivery |
| CN107595765A (zh) | 2017-09-22 | 2018-01-19 | 沈阳兴齐眼药股份有限公司 | 一种眼用缓释药物递送系统及其制备方法 |
| TW202027725A (zh) * | 2018-09-25 | 2020-08-01 | 愛爾蘭商托爾瑪國際有限公司 | 供藥物之延長投予之液體聚合物輸送系統 |
| EP4221688A1 (en) * | 2020-09-30 | 2023-08-09 | Tolmar International Limited | Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients |
| EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
| CN118284414A (zh) | 2021-07-06 | 2024-07-02 | M·哈斯莱顿 | 血清素再摄取抑制剂戒断综合征的治疗 |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
| AU2023281232A1 (en) | 2022-05-18 | 2024-10-24 | Laboratorios Farmacéuticos Rovi, S.A. | Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164374A1 (en) * | 1997-10-29 | 2002-11-07 | John Jackson | Polymeric systems for drug delivery and uses thereof |
| KR100416242B1 (ko) * | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
| KR100446101B1 (ko) | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
| AP1781A (en) | 2001-11-30 | 2007-09-27 | Pfizer | Controlled release polymeric compositions of bone growth promoting compounds. |
| GB0412866D0 (en) * | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
| KR101231856B1 (ko) * | 2004-08-12 | 2013-02-08 | 큐피에스 엘엘씨 | 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물 |
| US20070149631A1 (en) * | 2005-12-22 | 2007-06-28 | Haider Karl W | Base-catalyzed alkoxylation in the presense of polyoxyethylene-containing compounds |
-
2009
- 2009-08-11 EP EP09806425.6A patent/EP2323623B1/en active Active
- 2009-08-11 AU AU2009281223A patent/AU2009281223B2/en not_active Ceased
- 2009-08-11 JP JP2011522499A patent/JP5951991B2/ja active Active
- 2009-08-11 KR KR1020117003326A patent/KR101626632B1/ko not_active Expired - Fee Related
- 2009-08-11 BR BRPI0917975A patent/BRPI0917975A2/pt active Search and Examination
- 2009-08-11 PT PT98064256T patent/PT2323623T/pt unknown
- 2009-08-11 WO PCT/EP2009/060366 patent/WO2010018159A1/en not_active Ceased
- 2009-08-11 RU RU2011108666/15A patent/RU2504360C2/ru not_active IP Right Cessation
- 2009-08-11 CA CA2731316A patent/CA2731316C/en active Active
- 2009-08-11 US US13/058,074 patent/US9155696B2/en active Active
- 2009-08-11 MX MX2011001660A patent/MX347056B/es active IP Right Grant
- 2009-08-11 ES ES09806425.6T patent/ES2600797T3/es active Active
- 2009-08-11 CN CN200980131155.6A patent/CN102119022B/zh active Active
- 2009-08-11 PL PL09806425T patent/PL2323623T3/pl unknown
-
2015
- 2015-02-06 JP JP2015021998A patent/JP2015129145A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT2323623T (pt) | 2016-11-04 |
| AU2009281223A1 (en) | 2010-02-18 |
| CA2731316C (en) | 2017-10-03 |
| RU2011108666A (ru) | 2012-09-20 |
| MX347056B (es) | 2017-04-10 |
| MX2011001660A (es) | 2011-03-25 |
| JP2015129145A (ja) | 2015-07-16 |
| AU2009281223B2 (en) | 2014-01-09 |
| CA2731316A1 (en) | 2010-02-18 |
| KR20110042309A (ko) | 2011-04-26 |
| CN102119022A (zh) | 2011-07-06 |
| KR101626632B1 (ko) | 2016-06-01 |
| EP2323623B1 (en) | 2016-07-27 |
| WO2010018159A1 (en) | 2010-02-18 |
| CN102119022B (zh) | 2015-09-09 |
| US20110183905A1 (en) | 2011-07-28 |
| BRPI0917975A2 (pt) | 2015-11-17 |
| US9155696B2 (en) | 2015-10-13 |
| RU2504360C2 (ru) | 2014-01-20 |
| EP2323623A1 (en) | 2011-05-25 |
| ES2600797T3 (es) | 2017-02-10 |
| JP2011530568A (ja) | 2011-12-22 |
| JP5951991B2 (ja) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0814695D0 (en) | Pharmaceutical compositions | |
| PL2323623T3 (pl) | Kompozycje farmaceutyczne | |
| IL247741A0 (en) | pharmaceutical preparations | |
| IL228817A0 (en) | Pharmaceutical compounds | |
| EP2222313A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| IL211886A0 (en) | Solid pharmaceutical composition | |
| IL208387A0 (en) | Pharmaceutical composition | |
| GB0707127D0 (en) | Pharmaceutical compositions | |
| EP2146695A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| GB0709811D0 (en) | Pharmaceutical compositions | |
| ZA201100871B (en) | Solid pharmaceutical composition | |
| ZA201006224B (en) | Pharmaceutical composition | |
| IL206487A0 (en) | Pharmaceutical compositions | |
| GB2464200B (en) | Pharmaceutical composition | |
| GB0712454D0 (en) | Pharmaceutical compositions | |
| GB0817969D0 (en) | Pharmaceutical composition | |
| GB0800659D0 (en) | Pharmaceutical Compositions | |
| GB2454923B (en) | Pharmaceutical compositions | |
| IL201394A0 (en) | Niacin - based pharmaceutical compositions | |
| EP2236135A4 (en) | STABLE PHARMACEUTICAL COMPOSITION | |
| GB0806283D0 (en) | Pharmaceutical compositions | |
| GB0806156D0 (en) | Pharmaceutical compositions | |
| GB0802024D0 (en) | Pharmaceutical compositions | |
| EP2308842A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| GB0804485D0 (en) | Novel pharmaceutical compositions |